ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Treating Hyperuricemia Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-10D18147
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Drugs for Treating Hyperuricemia Market Research Report 2024
BUY CHAPTERS

Global Drugs for Treating Hyperuricemia Market Research Report 2024

Code: QYRE-Auto-10D18147
Report
August 2024
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
TEVA
Mylan Pharmaceuticals
Takeda Pharmaceuticals
Sanwa Kagaku Kenkyusho
Towa Pharmaceutical
TOA Eiyo
Astrazeneca plc
Mochida Pharmaceutical
Lannett Company
Horizo​​n Therapeutics
Sanofi
GSK
Fuji yakuhin

Drugs for Treating Hyperuricemia Market

Drugs used to treat hyperuricemia,a condition characterized by elevated levels of uric acid in the blood,primarily aim to lower uric acid levels to prevent complications such as gout and kidney stones.The most common medications include xanthine oxidase inhibitors like allopurinol and febuxostat,which reduce uric acid production by inhibiting the enzyme responsible for its formation.Another class,uricosuric agents such as probenecid,work by increasing uric acid excretion through the kidneys.
The global Drugs for Treating Hyperuricemia market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Drugs for Treating Hyperuricemia is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Drugs for Treating Hyperuricemia is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Drugs for Treating Hyperuricemia include Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Treating Hyperuricemia, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Treating Hyperuricemia.
The Drugs for Treating Hyperuricemia market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Drugs for Treating Hyperuricemia market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Treating Hyperuricemia manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Drugs for Treating Hyperuricemia Market Report

Report Metric Details
Report Name Drugs for Treating Hyperuricemia Market
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, Sanofi, GSK, Fuji Yakuhin
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Drugs for Treating Hyperuricemia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Drugs for Treating Hyperuricemia in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Drugs for Treating Hyperuricemia Market report?

Ans: The main players in the Drugs for Treating Hyperuricemia Market are Teva, Mylan Pharmaceuticals, Takeda Pharmaceuticals, Sanwa Kagaku Kenkyusho, Towa Pharmaceutical, Toa Eiyo, AstraZeneca, Mochida Pharmaceutical, Lannett Company, Horizo​​n Therapeutics, Sanofi, GSK, Fuji Yakuhin

What are the Application segmentation covered in the Drugs for Treating Hyperuricemia Market report?

Ans: The Applications covered in the Drugs for Treating Hyperuricemia Market report are Hospitals and Clinics, Retail Pharmacies, Other

What are the Type segmentation covered in the Drugs for Treating Hyperuricemia Market report?

Ans: The Types covered in the Drugs for Treating Hyperuricemia Market report are Uric Acid Production Inhibitors, Urate-stimulating Excretion Agents, Other

Recommended Reports

Uric Acid Disorders

Urinary System Therapy

Metabolic Disease Treatment

1 Drugs for Treating Hyperuricemia Market Overview
1.1 Product Definition
1.2 Drugs for Treating Hyperuricemia by Type
1.2.1 Global Drugs for Treating Hyperuricemia Market Value Comparison by Type (2024-2030)
1.2.2 Uric Acid Production Inhibitors
1.2.3 Urate-stimulating Excretion Agents
1.2.4 Other
1.3 Drugs for Treating Hyperuricemia by Application
1.3.1 Global Drugs for Treating Hyperuricemia Market Value by Application (2024-2030)
1.3.2 Hospitals and Clinics
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Drugs for Treating Hyperuricemia Market Size Estimates and Forecasts
1.4.1 Global Drugs for Treating Hyperuricemia Revenue 2019-2030
1.4.2 Global Drugs for Treating Hyperuricemia Sales 2019-2030
1.4.3 Global Drugs for Treating Hyperuricemia Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Drugs for Treating Hyperuricemia Market Competition by Manufacturers
2.1 Global Drugs for Treating Hyperuricemia Sales Market Share by Manufacturers (2019-2024)
2.2 Global Drugs for Treating Hyperuricemia Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Drugs for Treating Hyperuricemia Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Drugs for Treating Hyperuricemia, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Product Type & Application
2.7 Global Key Manufacturers of Drugs for Treating Hyperuricemia, Date of Enter into This Industry
2.8 Global Drugs for Treating Hyperuricemia Market Competitive Situation and Trends
2.8.1 Global Drugs for Treating Hyperuricemia Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Drugs for Treating Hyperuricemia Players Market Share by Revenue
2.8.3 Global Drugs for Treating Hyperuricemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Drugs for Treating Hyperuricemia Market Scenario by Region
3.1 Global Drugs for Treating Hyperuricemia Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Drugs for Treating Hyperuricemia Sales by Region: 2019-2030
3.2.1 Global Drugs for Treating Hyperuricemia Sales by Region: 2019-2024
3.2.2 Global Drugs for Treating Hyperuricemia Sales by Region: 2025-2030
3.3 Global Drugs for Treating Hyperuricemia Revenue by Region: 2019-2030
3.3.1 Global Drugs for Treating Hyperuricemia Revenue by Region: 2019-2024
3.3.2 Global Drugs for Treating Hyperuricemia Revenue by Region: 2025-2030
3.4 North America Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.4.1 North America Drugs for Treating Hyperuricemia Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Drugs for Treating Hyperuricemia Sales by Country (2019-2030)
3.4.3 North America Drugs for Treating Hyperuricemia Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.5.1 Europe Drugs for Treating Hyperuricemia Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Drugs for Treating Hyperuricemia Sales by Country (2019-2030)
3.5.3 Europe Drugs for Treating Hyperuricemia Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Drugs for Treating Hyperuricemia Market Facts & Figures by Region
3.6.1 Asia Pacific Drugs for Treating Hyperuricemia Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (2019-2030)
3.6.3 Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.7.1 Latin America Drugs for Treating Hyperuricemia Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Drugs for Treating Hyperuricemia Sales by Country (2019-2030)
3.7.3 Latin America Drugs for Treating Hyperuricemia Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Drugs for Treating Hyperuricemia Market Facts & Figures by Country
3.8.1 Middle East and Africa Drugs for Treating Hyperuricemia Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2019-2030)
3.8.3 Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Drugs for Treating Hyperuricemia Sales by Type (2019-2030)
4.1.1 Global Drugs for Treating Hyperuricemia Sales by Type (2019-2024)
4.1.2 Global Drugs for Treating Hyperuricemia Sales by Type (2025-2030)
4.1.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2019-2030)
4.2 Global Drugs for Treating Hyperuricemia Revenue by Type (2019-2030)
4.2.1 Global Drugs for Treating Hyperuricemia Revenue by Type (2019-2024)
4.2.2 Global Drugs for Treating Hyperuricemia Revenue by Type (2025-2030)
4.2.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2019-2030)
4.3 Global Drugs for Treating Hyperuricemia Price by Type (2019-2030)
5 Segment by Application
5.1 Global Drugs for Treating Hyperuricemia Sales by Application (2019-2030)
5.1.1 Global Drugs for Treating Hyperuricemia Sales by Application (2019-2024)
5.1.2 Global Drugs for Treating Hyperuricemia Sales by Application (2025-2030)
5.1.3 Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2019-2030)
5.2 Global Drugs for Treating Hyperuricemia Revenue by Application (2019-2030)
5.2.1 Global Drugs for Treating Hyperuricemia Revenue by Application (2019-2024)
5.2.2 Global Drugs for Treating Hyperuricemia Revenue by Application (2025-2030)
5.2.3 Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2019-2030)
5.3 Global Drugs for Treating Hyperuricemia Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Teva
6.1.1 Teva Company Information
6.1.2 Teva Description and Business Overview
6.1.3 Teva Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Teva Drugs for Treating Hyperuricemia Product Portfolio
6.1.5 Teva Recent Developments/Updates
6.2 Mylan Pharmaceuticals
6.2.1 Mylan Pharmaceuticals Company Information
6.2.2 Mylan Pharmaceuticals Description and Business Overview
6.2.3 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
6.2.5 Mylan Pharmaceuticals Recent Developments/Updates
6.3 Takeda Pharmaceuticals
6.3.1 Takeda Pharmaceuticals Company Information
6.3.2 Takeda Pharmaceuticals Description and Business Overview
6.3.3 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product Portfolio
6.3.5 Takeda Pharmaceuticals Recent Developments/Updates
6.4 Sanwa Kagaku Kenkyusho
6.4.1 Sanwa Kagaku Kenkyusho Company Information
6.4.2 Sanwa Kagaku Kenkyusho Description and Business Overview
6.4.3 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product Portfolio
6.4.5 Sanwa Kagaku Kenkyusho Recent Developments/Updates
6.5 Towa Pharmaceutical
6.5.1 Towa Pharmaceutical Company Information
6.5.2 Towa Pharmaceutical Description and Business Overview
6.5.3 Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Towa Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
6.5.5 Towa Pharmaceutical Recent Developments/Updates
6.6 Toa Eiyo
6.6.1 Toa Eiyo Company Information
6.6.2 Toa Eiyo Description and Business Overview
6.6.3 Toa Eiyo Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Toa Eiyo Drugs for Treating Hyperuricemia Product Portfolio
6.6.5 Toa Eiyo Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.7.4 AstraZeneca Drugs for Treating Hyperuricemia Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Mochida Pharmaceutical
6.8.1 Mochida Pharmaceutical Company Information
6.8.2 Mochida Pharmaceutical Description and Business Overview
6.8.3 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product Portfolio
6.8.5 Mochida Pharmaceutical Recent Developments/Updates
6.9 Lannett Company
6.9.1 Lannett Company Company Information
6.9.2 Lannett Company Description and Business Overview
6.9.3 Lannett Company Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Lannett Company Drugs for Treating Hyperuricemia Product Portfolio
6.9.5 Lannett Company Recent Developments/Updates
6.10 Horizo​​n Therapeutics
6.10.1 Horizo​​n Therapeutics Company Information
6.10.2 Horizo​​n Therapeutics Description and Business Overview
6.10.3 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product Portfolio
6.10.5 Horizo​​n Therapeutics Recent Developments/Updates
6.11 Sanofi
6.11.1 Sanofi Company Information
6.11.2 Sanofi Description and Business Overview
6.11.3 Sanofi Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sanofi Drugs for Treating Hyperuricemia Product Portfolio
6.11.5 Sanofi Recent Developments/Updates
6.12 GSK
6.12.1 GSK Company Information
6.12.2 GSK Description and Business Overview
6.12.3 GSK Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GSK Drugs for Treating Hyperuricemia Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Fuji Yakuhin
6.13.1 Fuji Yakuhin Company Information
6.13.2 Fuji Yakuhin Description and Business Overview
6.13.3 Fuji Yakuhin Drugs for Treating Hyperuricemia Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Fuji Yakuhin Drugs for Treating Hyperuricemia Product Portfolio
6.13.5 Fuji Yakuhin Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Drugs for Treating Hyperuricemia Industry Chain Analysis
7.2 Drugs for Treating Hyperuricemia Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Drugs for Treating Hyperuricemia Production Mode & Process
7.4 Drugs for Treating Hyperuricemia Sales and Marketing
7.4.1 Drugs for Treating Hyperuricemia Sales Channels
7.4.2 Drugs for Treating Hyperuricemia Distributors
7.5 Drugs for Treating Hyperuricemia Customers
8 Drugs for Treating Hyperuricemia Market Dynamics
8.1 Drugs for Treating Hyperuricemia Industry Trends
8.2 Drugs for Treating Hyperuricemia Market Drivers
8.3 Drugs for Treating Hyperuricemia Market Challenges
8.4 Drugs for Treating Hyperuricemia Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
TEVA
Mylan Pharmaceuticals
Takeda Pharmaceuticals
Sanwa Kagaku Kenkyusho
Towa Pharmaceutical
TOA Eiyo
Astrazeneca plc
Mochida Pharmaceutical
Lannett Company
Horizo​​n Therapeutics
Sanofi
GSK
Fuji yakuhin
List of Tables
 Table 1. Global Drugs for Treating Hyperuricemia Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Drugs for Treating Hyperuricemia Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Drugs for Treating Hyperuricemia Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Drugs for Treating Hyperuricemia Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Drugs for Treating Hyperuricemia Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Drugs for Treating Hyperuricemia Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Drugs for Treating Hyperuricemia Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Drugs for Treating Hyperuricemia, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Product Type & Application
 Table 12. Global Key Manufacturers of Drugs for Treating Hyperuricemia, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Drugs for Treating Hyperuricemia by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Hyperuricemia as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Drugs for Treating Hyperuricemia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Drugs for Treating Hyperuricemia Sales by Region (2019-2024) & (K Units)
 Table 18. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2019-2024)
 Table 19. Global Drugs for Treating Hyperuricemia Sales by Region (2025-2030) & (K Units)
 Table 20. Global Drugs for Treating Hyperuricemia Sales Market Share by Region (2025-2030)
 Table 21. Global Drugs for Treating Hyperuricemia Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2019-2024)
 Table 23. Global Drugs for Treating Hyperuricemia Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Drugs for Treating Hyperuricemia Revenue Market Share by Region (2025-2030)
 Table 25. North America Drugs for Treating Hyperuricemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Drugs for Treating Hyperuricemia Sales by Country (2019-2024) & (K Units)
 Table 27. North America Drugs for Treating Hyperuricemia Sales by Country (2025-2030) & (K Units)
 Table 28. North America Drugs for Treating Hyperuricemia Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Drugs for Treating Hyperuricemia Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Drugs for Treating Hyperuricemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Drugs for Treating Hyperuricemia Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Drugs for Treating Hyperuricemia Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Drugs for Treating Hyperuricemia Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Drugs for Treating Hyperuricemia Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Drugs for Treating Hyperuricemia Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Drugs for Treating Hyperuricemia Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Drugs for Treating Hyperuricemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Drugs for Treating Hyperuricemia Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Drugs for Treating Hyperuricemia Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Drugs for Treating Hyperuricemia Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Drugs for Treating Hyperuricemia Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Drugs for Treating Hyperuricemia Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Drugs for Treating Hyperuricemia Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Drugs for Treating Hyperuricemia Sales (K Units) by Type (2019-2024)
 Table 51. Global Drugs for Treating Hyperuricemia Sales (K Units) by Type (2025-2030)
 Table 52. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2019-2024)
 Table 53. Global Drugs for Treating Hyperuricemia Sales Market Share by Type (2025-2030)
 Table 54. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2019-2024)
 Table 57. Global Drugs for Treating Hyperuricemia Revenue Market Share by Type (2025-2030)
 Table 58. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Drugs for Treating Hyperuricemia Sales (K Units) by Application (2019-2024)
 Table 61. Global Drugs for Treating Hyperuricemia Sales (K Units) by Application (2025-2030)
 Table 62. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2019-2024)
 Table 63. Global Drugs for Treating Hyperuricemia Sales Market Share by Application (2025-2030)
 Table 64. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Drugs for Treating Hyperuricemia Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2019-2024)
 Table 67. Global Drugs for Treating Hyperuricemia Revenue Market Share by Application (2025-2030)
 Table 68. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2025-2030)
 Table 70. Teva Company Information
 Table 71. Teva Description and Business Overview
 Table 72. Teva Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Teva Drugs for Treating Hyperuricemia Product
 Table 74. Teva Recent Developments/Updates
 Table 75. Mylan Pharmaceuticals Company Information
 Table 76. Mylan Pharmaceuticals Description and Business Overview
 Table 77. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Mylan Pharmaceuticals Drugs for Treating Hyperuricemia Product
 Table 79. Mylan Pharmaceuticals Recent Developments/Updates
 Table 80. Takeda Pharmaceuticals Company Information
 Table 81. Takeda Pharmaceuticals Description and Business Overview
 Table 82. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Takeda Pharmaceuticals Drugs for Treating Hyperuricemia Product
 Table 84. Takeda Pharmaceuticals Recent Developments/Updates
 Table 85. Sanwa Kagaku Kenkyusho Company Information
 Table 86. Sanwa Kagaku Kenkyusho Description and Business Overview
 Table 87. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Sanwa Kagaku Kenkyusho Drugs for Treating Hyperuricemia Product
 Table 89. Sanwa Kagaku Kenkyusho Recent Developments/Updates
 Table 90. Towa Pharmaceutical Company Information
 Table 91. Towa Pharmaceutical Description and Business Overview
 Table 92. Towa Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Towa Pharmaceutical Drugs for Treating Hyperuricemia Product
 Table 94. Towa Pharmaceutical Recent Developments/Updates
 Table 95. Toa Eiyo Company Information
 Table 96. Toa Eiyo Description and Business Overview
 Table 97. Toa Eiyo Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Toa Eiyo Drugs for Treating Hyperuricemia Product
 Table 99. Toa Eiyo Recent Developments/Updates
 Table 100. AstraZeneca Company Information
 Table 101. AstraZeneca Description and Business Overview
 Table 102. AstraZeneca Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. AstraZeneca Drugs for Treating Hyperuricemia Product
 Table 104. AstraZeneca Recent Developments/Updates
 Table 105. Mochida Pharmaceutical Company Information
 Table 106. Mochida Pharmaceutical Description and Business Overview
 Table 107. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Mochida Pharmaceutical Drugs for Treating Hyperuricemia Product
 Table 109. Mochida Pharmaceutical Recent Developments/Updates
 Table 110. Lannett Company Company Information
 Table 111. Lannett Company Description and Business Overview
 Table 112. Lannett Company Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Lannett Company Drugs for Treating Hyperuricemia Product
 Table 114. Lannett Company Recent Developments/Updates
 Table 115. Horizo​​n Therapeutics Company Information
 Table 116. Horizo​​n Therapeutics Description and Business Overview
 Table 117. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Horizo​​n Therapeutics Drugs for Treating Hyperuricemia Product
 Table 119. Horizo​​n Therapeutics Recent Developments/Updates
 Table 120. Sanofi Company Information
 Table 121. Sanofi Description and Business Overview
 Table 122. Sanofi Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 123. Sanofi Drugs for Treating Hyperuricemia Product
 Table 124. Sanofi Recent Developments/Updates
 Table 125. GSK Company Information
 Table 126. GSK Description and Business Overview
 Table 127. GSK Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 128. GSK Drugs for Treating Hyperuricemia Product
 Table 129. GSK Recent Developments/Updates
 Table 130. Fuji Yakuhin Company Information
 Table 131. Fuji Yakuhin Description and Business Overview
 Table 132. Fuji Yakuhin Drugs for Treating Hyperuricemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 133. Fuji Yakuhin Drugs for Treating Hyperuricemia Product
 Table 134. Fuji Yakuhin Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Drugs for Treating Hyperuricemia Distributors List
 Table 138. Drugs for Treating Hyperuricemia Customers List
 Table 139. Drugs for Treating Hyperuricemia Market Trends
 Table 140. Drugs for Treating Hyperuricemia Market Drivers
 Table 141. Drugs for Treating Hyperuricemia Market Challenges
 Table 142. Drugs for Treating Hyperuricemia Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Drugs for Treating Hyperuricemia
 Figure 2. Global Drugs for Treating Hyperuricemia Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Drugs for Treating Hyperuricemia Market Share by Type: 2023 & 2030
 Figure 4. Uric Acid Production Inhibitors Product Picture
 Figure 5. Urate-stimulating Excretion Agents Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Drugs for Treating Hyperuricemia Market Value by Application (2024-2030) & (US$ Million)
 Figure 8. Global Drugs for Treating Hyperuricemia Market Share by Application: 2023 & 2030
 Figure 9. Hospitals and Clinics
 Figure 10. Retail Pharmacies
 Figure 11. Other
 Figure 12. Global Drugs for Treating Hyperuricemia Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 13. Global Drugs for Treating Hyperuricemia Market Size (2019-2030) & (US$ Million)
 Figure 14. Global Drugs for Treating Hyperuricemia Sales (2019-2030) & (K Units)
 Figure 15. Global Drugs for Treating Hyperuricemia Average Price (US$/Unit) & (2019-2030)
 Figure 16. Drugs for Treating Hyperuricemia Report Years Considered
 Figure 17. Drugs for Treating Hyperuricemia Sales Share by Manufacturers in 2023
 Figure 18. Global Drugs for Treating Hyperuricemia Revenue Share by Manufacturers in 2023
 Figure 19. Global 5 and 10 Largest Drugs for Treating Hyperuricemia Players: Market Share by Revenue in Drugs for Treating Hyperuricemia in 2023
 Figure 20. Drugs for Treating Hyperuricemia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 21. Global Drugs for Treating Hyperuricemia Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 22. North America Drugs for Treating Hyperuricemia Sales Market Share by Country (2019-2030)
 Figure 23. North America Drugs for Treating Hyperuricemia Revenue Market Share by Country (2019-2030)
 Figure 24. United States Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Canada Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Europe Drugs for Treating Hyperuricemia Sales Market Share by Country (2019-2030)
 Figure 27. Europe Drugs for Treating Hyperuricemia Revenue Market Share by Country (2019-2030)
 Figure 28. Germany Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. France Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. U.K. Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Italy Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Russia Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Asia Pacific Drugs for Treating Hyperuricemia Sales Market Share by Region (2019-2030)
 Figure 34. Asia Pacific Drugs for Treating Hyperuricemia Revenue Market Share by Region (2019-2030)
 Figure 35. China Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. Japan Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. South Korea Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. India Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. Australia Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. China Taiwan Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Southeast Asia Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Latin America Drugs for Treating Hyperuricemia Sales Market Share by Country (2019-2030)
 Figure 43. Mexico Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Brazil Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Argentina Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Colombia Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Middle East and Africa Drugs for Treating Hyperuricemia Sales Market Share by Country (2019-2030)
 Figure 48. Middle East and Africa Drugs for Treating Hyperuricemia Revenue Market Share by Country (2019-2030)
 Figure 49. Turkey Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. Saudi Arabia Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. UAE Drugs for Treating Hyperuricemia Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Global Sales Market Share of Drugs for Treating Hyperuricemia by Type (2019-2030)
 Figure 53. Global Revenue Market Share of Drugs for Treating Hyperuricemia by Type (2019-2030)
 Figure 54. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Type (2019-2030)
 Figure 55. Global Sales Market Share of Drugs for Treating Hyperuricemia by Application (2019-2030)
 Figure 56. Global Revenue Market Share of Drugs for Treating Hyperuricemia by Application (2019-2030)
 Figure 57. Global Drugs for Treating Hyperuricemia Price (US$/Unit) by Application (2019-2030)
 Figure 58. Drugs for Treating Hyperuricemia Value Chain
 Figure 59. Drugs for Treating Hyperuricemia Production Process
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global Uric Acid lowering Drugs Market Research Report 2024
Global Xanthine Oxidase Inhibitors for the Treatment of Hyperuricemia Market Research Report 2024
Global Uric Acid Production Inhibitors Market Research Report 2024
Global Topiroxostat Tablets Market Research Report 2024
Global Dotinurad Tablets Market Research Report 2024
Global Probenecid Tablets Market Research Report 2024
Global Febuxostat API Market Research Report 2024
Global Urate stimulating Excretion Agents Market Research Report 2024
Global Hyperuricemia Micromolecular Drugs Market Research Report 2024
Global Chronic Gout Treatment Drug Market Research Report 2024
Antihyperuricemic Agents Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Drugs for the Treatment of Refractory Gout Market Research Report 2024
Uric Acid Health Supplement Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Uric Acid Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benzbromarone Tablets Market Research Report 2024
Drugs for Amino Acid Metabolism Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Uric Acid Analyzer Market Research Report 2024
Global Interleukin Inhibitors for the Treatment of Refractory Gout Market Research Report 2024
Amino Acid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ursodeoxycholic Acid Drug Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions